Alpha-Synuclein: Adding Precision to Neurodegenerative Testing

In this episode of Clinical Lab Chat, CLP’s Director of Business Intelligence, Chris Wolski, discusses the how and why of making precise clinical diagnosis of neurodegenerative diseases with Russ Lebovitz, MD, PhD, co-founder and CEO of Amprion. Among the topics they discuss:The critical importance of making accurate diagnoses of neurodegenerative diseasesWhy alpha-synuclein is an accurate biomarker for a number of degenerative diseases, including Alzheimer’sHow adding neurodegenerative testing to the routine diagnostic menu would benefit patients and their caregiversWhy we’re entering a neurological healthcare “golden age”